Telix Appoints David Gill as Chair

Telix Pharmaceuticals announced that David Gill has been appointed as Chair of the Board, effective immediately. Gill, who joined as a Non-Executive Director in May 2026, brings over 35 years of life sciences executive experience, including expertise in radiopharmaceuticals, capital markets, and corporate strategy. He succeeds Dr. Mark Nelson, who served as interim Chair and will remain as a Non-Executive Director.